MIRA Pharmaceuticals, Inc. (MIRA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

MIRA Pharmaceuticals, Inc. (MIRA) Healthcare & Pipeline Overview

MIRA Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing MIRA1a, a synthetic THC analog, for anxiety and cognitive decline linked to early-stage dementia. Targeting cannabinoid type 1 and 2 receptors, MIRA aims to address chronic pain, positioning itself in the evolving landscape of cannabinoid-based therapeutics.

What Is the Investment Thesis for MIRA?

MIRA Pharmaceuticals presents a high-risk, high-reward investment opportunity characteristic of early-stage biopharmaceutical companies. The company's focus on MIRA1a, a synthetic THC analog, for treating anxiety and cognitive decline in early-stage dementia, addresses a significant unmet medical need. A successful clinical trial outcome could drive substantial value, given the increasing prevalence of dementia and the limitations of existing treatments. However, the company's small market capitalization of $33.2M and limited operating history introduce considerable uncertainty. The beta of 1.94 indicates high volatility. Investment hinges on the successful navigation of clinical trials and regulatory pathways, with potential for significant upside if MIRA1a demonstrates efficacy and safety.

Based on FMP financials and quantitative analysis

MIRA Key Highlights

MIRA Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing MIRA1a, a synthetic THC analog.

• The company targets cannabinoid type 1 and type 2 receptors to treat anxiety and chronic pain.
• MIRA1a is under investigation for the treatment of adult patients with anxiety and cognitive decline associated with early-stage dementia.
• The company was incorporated in 2020 and is headquartered in Baltimore, Maryland.
• MIRA Pharmaceuticals has a market capitalization of $33.2M and a beta of 1.94, indicating high volatility.

Who Are MIRA's Competitors?

MIRA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are MIRA's Key Strengths?

Focus on a specific unmet medical need (anxiety and cognitive decline in early-stage dementia).

• Proprietary synthetic cannabinoid technology.
• Potential for targeted therapy with MIRA1a.
• Experienced management team in drug development.

What Are MIRA's Weaknesses?

Early-stage clinical development with high risk of failure.

• Limited financial resources.
• Small team size (2 employees).
• Reliance on a single drug candidate (MIRA1a).

What Could Drive MIRA Stock Higher?

Initiation of Phase 1 clinical trials for MIRA1a.

• Announcement of interim results from Phase 1 clinical trials.
• Progress in securing partnerships with pharmaceutical companies.
• Advancements in intellectual property protection for MIRA1a.

What Are the Key Risks for MIRA?

Listing risk — at $0.7892 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure to obtain regulatory approvals for MIRA1a.
• Clinical trial failures or delays.
• Competition from other companies developing treatments for anxiety and dementia.
• Limited financial resources and dependence on external funding.
• Negative perception of cannabinoid-based therapies.

What Are the Growth Opportunities for MIRA?

• Advancement of MIRA1a through Clinical Trials: MIRA Pharmaceuticals' primary growth opportunity lies in successfully advancing MIRA1a through clinical trials. Positive results in Phase 1, 2, and 3 trials would validate the drug's efficacy and safety, significantly increasing its market value. The timeline for clinical trials can vary, but typically spans several years, with each phase requiring substantial investment. Success in this area would open up a multi-billion dollar market for dementia and anxiety treatments.
• Partnerships and Collaborations: MIRA Pharmaceuticals can pursue strategic partnerships with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of MIRA1a. Collaborations can provide access to additional funding, expertise, and resources, reducing the financial burden on MIRA. These partnerships could also facilitate the expansion of MIRA1a's applications to other neurological or psychiatric disorders, broadening its market potential. The timeline for securing partnerships can vary, but typically involves extensive negotiations and due diligence.
• Expansion of the Drug Pipeline: MIRA Pharmaceuticals can expand its drug pipeline by developing additional synthetic cannabinoid analogs targeting other indications beyond anxiety and dementia. This diversification would reduce the company's reliance on MIRA1a and create new revenue streams. Potential targets include chronic pain, epilepsy, and other neurological disorders. The development of new drugs requires significant investment in research and development, and the timeline for bringing new drugs to market can be lengthy.
• Intellectual Property Protection: Securing and maintaining strong intellectual property protection for MIRA1a and other drug candidates is crucial for MIRA Pharmaceuticals' long-term growth. Patents can provide exclusive rights to manufacture and market the drugs, preventing competitors from entering the market. The company should actively pursue patent applications and defend its intellectual property rights against infringement. The timeline for obtaining patents can vary, but typically takes several years.
• Regulatory Approvals and Market Access: Obtaining regulatory approvals from agencies such as the FDA is essential for commercializing MIRA1a. The approval process involves submitting extensive data on the drug's safety and efficacy. Once approved, MIRA Pharmaceuticals needs to secure market access by negotiating favorable reimbursement rates with insurance companies and government healthcare programs. The timeline for regulatory approvals and market access can be lengthy and uncertain.

What Are MIRA's Competitive Advantages?

• Patented synthetic cannabinoid analogs provide intellectual property protection.
• First-mover advantage in developing synthetic THC analogs for specific medical conditions.
• Proprietary knowledge and expertise in cannabinoid receptor targeting.
• Established relationships with key opinion leaders and researchers in the field.

What Does MIRA Do?

MIRA Pharmaceuticals, Inc., incorporated in 2020 and headquartered in Baltimore, Maryland, is a clinical development stage biopharmaceutical company. The company is dedicated to the development and commercialization of innovative therapies, particularly focusing on a novel molecular synthetic tetrahydrocannabinol (THC) analog. Their lead investigational drug, MIRA1a, is being developed for the treatment of adult patients suffering from anxiety and cognitive decline, symptoms often associated with early-stage dementia. MIRA1a is a synthetic cannabinoid analog designed to target both cannabinoid type 1 (CB1) and type 2 (CB2) receptors, aiming to alleviate anxiety and chronic pain. Formerly known as MIRA1a Therapeutics, Inc., the company is committed to advancing its research and development efforts to bring new treatment options to patients with unmet medical needs in the areas of neurological and psychiatric disorders. The company's focus on synthetic cannabinoids allows for precise control over the drug's composition and effects, potentially offering advantages over naturally derived cannabinoids. MIRA Pharmaceuticals is currently in the early stages of clinical development, and its success depends on the successful completion of clinical trials and regulatory approval.

What Products and Services Does MIRA Offer?

• Develops synthetic THC analogs for medical applications.
• Focuses on treating anxiety and cognitive decline associated with early-stage dementia.
• Targets cannabinoid type 1 and type 2 receptors with its lead drug candidate, MIRA1a.
• Conducts clinical trials to evaluate the safety and efficacy of MIRA1a.
• Seeks regulatory approval from agencies like the FDA.
• Aims to commercialize MIRA1a for the treatment of anxiety and chronic pain.

How Does MIRA Make Money?

• Develops and patents novel synthetic cannabinoid compounds.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval for its drug candidates.
• Commercializes approved drugs through partnerships or direct sales.

What Industry Does MIRA Operate In?

MIRA Pharmaceuticals operates within the drug manufacturers industry, a segment of the broader healthcare sector. This industry is characterized by intense research and development, stringent regulatory requirements, and high capital investment. The market for dementia treatments is substantial and growing, driven by an aging global population. Competition includes both established pharmaceutical companies and smaller biotech firms, all vying to develop effective therapies. MIRA's focus on synthetic cannabinoids positions it within a niche area that is gaining increasing attention, but also faces regulatory and perception-related challenges.

Who Are MIRA's Key Customers?

• Adult patients with anxiety and cognitive decline associated with early-stage dementia.
• Patients suffering from chronic pain.
• Healthcare providers who prescribe medications for neurological and psychiatric disorders.
• Pharmaceutical companies interested in licensing or acquiring MIRA's drug candidates.

How MIRA Pharmaceuticals, Inc. Is Valued

MIRA Pharmaceuticals, Inc. carries a market capitalization of $33.2M, placing it in the micro-cap category. Relative to its peer group, MIRA's quantitative score of 48/100 is roughly in line with the peer average of 51/100.

Company Profile

MIRA Pharmaceuticals, Inc. operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Miami, US. The company is led by CEO Erez Aminov. MIRA has traded publicly since 2023.

Key Financial Metrics

Its free cash flow yield is -10.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 82.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -24.9%, the inverse of the P/E and a quick read on earnings relative to price.

MIRA Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

MIRA Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 23.7% below estimates on average.

Wall Street analysts project MIRA Pharmaceuticals, Inc. revenue of about $276.0M for fiscal 2026, with EPS near $-0.18.

Over the past six months, MIRA Pharmaceuticals, Inc. insiders filed 5 SEC Form 4 transactions — 0 sales and 5 purchases. On net that is roughly 284K shares acquired (about $188K) — insiders putting money in tends to read as conviction.

MIRA Financials

MIRA Latest News

MIRA Analyst Consensus

MIRA MoonshotScore

MIRA Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources